Literature DB >> 7396771

Incidence of retinoblastoma in the United States.

T W Pendergrass, S Davis.   

Abstract

Data from the population-based Surveillance, Epidemiology, and End Results Program of the National Cancer Institute were used to calculate the incidence of retinoblastoma for the years 1974 through 1976. Each year 3.58 cases occurred for each million children under the age of 15 years. Incidence was markedly age related, with over 90% of the cases being diagnosed before the age of 5 years. Although no difference in incidence was found for whites and blacks, other nonwhites had rates greater than four times those of whites. Twenty percent of patients had bilateral disease. Treatment patterns revealed that surgery remains the most common treatment modality. Review of patterns of survival suggested that children in the other nonwhites category with unilateral disease had poorest survival rates.

Entities:  

Mesh:

Year:  1980        PMID: 7396771     DOI: 10.1001/archopht.1980.01020040056003

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  31 in total

1.  New and recurrent tumor foci following local treatment as well as external beam radiation in eyes of patients with hereditary retinoblastoma.

Authors:  E P Messmer; W Sauerwein; T Heinrich; W Höpping; D Klueter-Reckmann; N Bornfeld; H Sack; M Förster; W Havers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 2.  The diagnosis of retinoblastoma.

Authors:  D H Abramson
Journal:  Bull N Y Acad Med       Date:  1988-05

3.  Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Christina Decatur; Timothy G Murray; Samuel K Houston; Milena Lopez-Cavalcante; Eleut Hernandez; Magda Celdran; Nikesh Shah; William Feuer; Theodore Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

4.  Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Authors:  Samuel K Houston; Yolanda Pina; Jennifer Clarke; Tulay Koru-Sengul; William K Scott; Lubov Nathanson; Amy C Schefler; Timothy G Murray
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

5.  Eye cancer incidence in Singapore.

Authors:  S B Lee; K G Au Eong; S M Saw; T K Chan; H P Lee
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

6.  Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995.

Authors:  A C Moll; D J Kuik; L M Bouter; W Den Otter; P D Bezemer; J W Koten; S M Imhof; B P Kuyt; K E Tan
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

7.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.

Authors:  Jeannette R Wong; Lindsay M Morton; Margaret A Tucker; David H Abramson; Johanna M Seddon; Joshua N Sampson; Ruth A Kleinerman
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

8.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

9.  Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Authors:  Yolanda Piña; Hinda Boutrid; Timothy G Murray; Martine J Jager; Colleen M Cebulla; Amy Schefler; Long V Ly; Armando Alegret; Magda Celdran; William Feuer; Maria-Elena Jockovich
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

10.  Retinoblastoma mutation rate in New Zealand and support for the two-hit model.

Authors:  P H Fitzgerald; J Stewart; R D Suckling
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.